# Royal Jelly Supplementation Improves Endurance and Mitochondrial Biogenesis in Athletes: A Crossover Trial

**Authors:** Yahya Pasdar, Vahid Tadibi, Ehsan Sadeghi, Farid Najafi, Mohammadreza Abbaspour, Amir Saber, Zahra Ghorbani, Shima Sharifi, Mahsa Miryan

PMC · DOI: 10.1002/fsn3.70497 · Food Science & Nutrition · 2025-07-16

## TL;DR

Royal jelly improved endurance and mitochondrial activity in athletes, but had no effect on oxidative stress or other factors.

## Contribution

First crossover trial showing royal jelly's selective ergogenic effects on endurance and PGC-1α expression in trained athletes.

## Key findings

- RJ increased time to exhaustion by 4.63 minutes compared to placebo.
- RJ significantly upregulated PGC-1α gene expression.
- No significant changes in oxidative stress markers or Nrf2 expression.

## Abstract

Royal jelly (RJ) has been shown in animal models to alleviate muscle fatigue and damage during exercise. This trial was designed to assess the effect of RJ on exercise performance, oxidative stress, and nuclear factor erythroid 2‐related factor 2 (Nrf2) and peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha (PGC‐1α) expression in endurance‐trained male athletes. In this randomized, crossover trial, 18 eligible participants were randomly assigned to receive RJ (1000 mg/day) in one period and placebo in another period for 2 weeks, with a 2‐week washout. The exhaustive endurance‐running test was conducted to assess time to exhaustion (TTE), perceived exertion, arousal levels, and affective response. Blood samples were collected to assess gene expression, malondialdehyde (MDA), total antioxidant capacity (TAC), and total oxidant status (TOS). The carryover and sequence effects were not significant for all outcomes (p‐value > 0.05). The mean changes from baseline were statistically significant for TTE (7.32; 95% CI: 4.61–10.02; p‐value: 0.001), post‐exercise TOS (−18.56; 95% CI: −31.61 to −5.51; p‐value: 0.008), and PGC‐1α expression (2.23; 95% CI: 0.49–3.98; p‐value: 0.015) with RJ, and TTE (2.69; 95% CI: 0.80–4.59; p‐value: 0.008) with placebo. The treatment differences in TTE and PGC‐1α expression relative to placebo were 4.63 min (95% CI: 1.78–7.48; p‐value: 0.002) and 2.12 (95% CI: 0.16–4.09; p‐value: 0.035), respectively. No significant effects were observed in Nrf2 expression, perceived exertion, arousal levels, affective response, heart rate, and other oxidative stress markers. RJ supplementation improved endurance capacity and PGC‐1α expression but had no significant effect on oxidative stress and Nrf2 expression in endurance‐trained athletes, suggesting selective ergogenic effects. Further studies are needed to evaluate its efficacy across different athlete populations.

This clinical trial showed that royal jelly supplementation significantly improved athletic performance by increasing the time to exhaustion and peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha (PGC‐1α) gene expression during the exhaustive endurance‐running test. However, its supplementation had no significant effects on nuclear factor erythroid 2‐related factor 2 (Nrf2) gene expression, malondialdehyde (MDA), total antioxidant capacity (TAC), total oxidant status (TOS), heart rate, rate of perceived exertion (RPE), arousal, and pleasure to exercise [Up Arrow (Increase); Double‐sided Arrow (Without Change)].

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891]
- **Chemicals:** malondialdehyde (PubChem CID 10964)

## Full-text entities

- **Genes:** PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}
- **Diseases:** muscle fatigue (MESH:D005221)
- **Chemicals:** RJ (MESH:C058787), MDA (MESH:D008315)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12267883/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12267883/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC12267883/full.md

---
Source: https://tomesphere.com/paper/PMC12267883